{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-047560","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2022-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.366468+00:00","generated_at":"2026-06-26T06:15:38.266775+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Abbott Q1 sales $11.9B (+13.8%), adjusted EPS $1.73; full-year guidance reaffirmed","bullets":["Q1 sales $11.9B, +13.8% reported, +17.5% organic; GAAP EPS $1.37, adjusted EPS $1.73.","Global COVID-19 testing sales $3.3B in Q1; full-year testing sales projected ~$4.5B, mostly in H1.","Full-year 2022 adjusted EPS guidance reaffirmed at least $4.70; GAAP EPS at least $3.35.","Nutrition sales -7% reported (-4.4% organic) due to infant formula recall; excluding recall, Nutrition +5%.","Medical Devices +7.4% reported (+11.5% organic); FreeStyle Libre sales ~$1.0B (+20.4% reported)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-047560","json":"https://secwatch.observer/filing/0001104659-22-047560.json","markdown":"https://secwatch.observer/filing/0001104659-22-047560.md","text":"https://secwatch.observer/filing/0001104659-22-047560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000110465922047560/0001104659-22-047560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000110465922047560/tm2213006d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T06:15:38.266775+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}